Literature DB >> 33526120

Overbaked: assessing and predicting acute adverse reactions to Cannabis.

Emily M LaFrance1, Amanda Stueber2, Nicholas C Glodosky2, Dakota Mauzay2, Carrie Cuttler2,3.   

Abstract

BACKGROUND: Trends toward legalizing cannabis may increase experimentation with the drug among less experienced users with limited knowledge of possible adverse reactions. This study explores the prevalence, frequency, and levels of distress produced by various acute adverse reactions to cannabis, as well as predictors of these reactions.
METHODS: The Adverse Reactions Scale (ARS) was created and administered to a large sample of undergraduate college students (n = 999) who were predominantly white (> 70%), female (> 70%), recreational (> 90%) cannabis users. The ARS was administered in an anonymous online survey measuring demographics, cannabis use patterns, cannabis use motives, personality, and negative affect.
RESULTS: The most prevalent adverse reactions to cannabis were coughing fits, anxiety, and paranoia, which > 50% of the sample reported experiencing. The most frequently occurring reactions were coughing fits, chest/lung discomfort, and body humming, which occurred on approximately 30-40% of cannabis use sessions. Panic attacks, fainting, and vomiting were rated as the most distressing, with mean ratings falling between "moderately" and "quite" distressing. Multiple regression analyses revealed that lower frequency of cannabis use predicted increased frequency of adverse reactions. Symptoms of cannabis use disorder, conformity motives, and anxiety sensitivity were significant predictors of both the prevalence of, and distress caused by, adverse reactions.
CONCLUSIONS: Relative to past research, this study provides a more comprehensive account of possible adverse reactions to cannabis, and individual difference variables that predict these reactions. This study has implications for inexperienced cannabis users, as well as medical professionals and budtenders who provide information about cannabis use.

Entities:  

Keywords:  Adverse reactions; Anxiety; Cannabis use; Paranoia; Side effects

Year:  2020        PMID: 33526120      PMCID: PMC7819287          DOI: 10.1186/s42238-019-0013-x

Source DB:  PubMed          Journal:  J Cannabis Res        ISSN: 2522-5782


  11 in total

1.  An improved brief measure of cannabis misuse: the Cannabis Use Disorders Identification Test-Revised (CUDIT-R).

Authors:  Simon J Adamson; Frances J Kay-Lambkin; Amanda L Baker; Terry J Lewin; Louise Thornton; Brian J Kelly; J Douglas Sellman
Journal:  Drug Alcohol Depend       Date:  2010-03-26       Impact factor: 4.492

2.  Testing the self-medication hypothesis of depression and aggression in cannabis-dependent subjects.

Authors:  Mikkel Arendt; Raben Rosenberg; Lone Fjordback; Jack Brandholdt; Leslie Foldager; Leo Sher; Povl Munk-Jørgensen
Journal:  Psychol Med       Date:  2007-01-04       Impact factor: 7.723

3.  Development and preliminary validation of a self-report measure of psychopathic personality traits in noncriminal populations.

Authors:  S O Lilienfeld; B P Andrews
Journal:  J Pers Assess       Date:  1996-06

4.  Acute effects of smoked marijuana in marijuana smokers at clinical high-risk for psychosis: A preliminary study.

Authors:  Nehal P Vadhan; Cheryl M Corcoran; Gill Bedi; John G Keilp; Margaret Haney
Journal:  Psychiatry Res       Date:  2017-08-01       Impact factor: 3.222

5.  Reliability and validity of the Marijuana Motives Measure among young adult frequent cannabis users and associations with cannabis dependence.

Authors:  Annemieke Benschop; Nienke Liebregts; Peggy van der Pol; Rick Schaap; Renate Buisman; Margriet van Laar; Wim van den Brink; Ron de Graaf; Dirk J Korf
Journal:  Addict Behav       Date:  2014-09-09       Impact factor: 3.913

6.  Relations between cannabis use and dependence, motives for cannabis use and anxious, depressive and borderline symptomatology.

Authors:  Henri Chabrol; Emmanuelle Ducongé; Carine Casas; Charlotte Roura; Kate B Carey
Journal:  Addict Behav       Date:  2005-05       Impact factor: 3.913

7.  The Depression Anxiety Stress Scales-21 (DASS-21): further examination of dimensions, scale reliability, and correlates.

Authors:  Augustine Osman; Jane L Wong; Courtney L Bagge; Stacey Freedenthal; Peter M Gutierrez; Gregorio Lozano
Journal:  J Clin Psychol       Date:  2012-08-28

8.  Coping-motivated marijuana use correlates with DSM-5 cannabis use disorder and psychological distress among emerging adults.

Authors:  Ethan Moitra; Paul P Christopher; Bradley J Anderson; Michael D Stein
Journal:  Psychol Addict Behav       Date:  2015-04-27

9.  A Cross-Sectional Survey of Medical Cannabis Users: Patterns of Use and Perceived Efficacy.

Authors:  Michelle Sexton; Carrie Cuttler; John S Finnell; Laurie K Mischley
Journal:  Cannabis Cannabinoid Res       Date:  2016-06-01

10.  A Survey of Cannabis Acute Effects and Withdrawal Symptoms: Differential Responses Across User Types and Age.

Authors:  Michelle Sexton; Carrie Cuttler; Laurie K Mischley
Journal:  J Altern Complement Med       Date:  2018-10-31       Impact factor: 2.579

View more
  4 in total

Review 1.  Medical Cannabis for Headache Pain: a Primer for Clinicians.

Authors:  Robert A Duarte; Stephen Dahmer; Shayna Y Sanguinetti; Grace Forde; Diana P Duarte; Lawrence F Kobak
Journal:  Curr Pain Headache Rep       Date:  2021-10-09

2.  Reasons for cannabidiol use: a cross-sectional study of CBD users, focusing on self-perceived stress, anxiety, and sleep problems.

Authors:  Julie Moltke; Chandni Hindocha
Journal:  J Cannabis Res       Date:  2021-02-18

3.  Rates and correlates of cannabis-associated psychotic symptoms in over 230,000 people who use cannabis.

Authors:  Tabea Schoeler; Jason Ferris; Adam R Winstock
Journal:  Transl Psychiatry       Date:  2022-09-06       Impact factor: 7.989

4.  Pilot clinical and pharmacokinetic study of Δ9-Tetrahydrocannabinol (THC)/Cannabidiol (CBD) nanoparticle oro-buccal spray in patients with advanced cancer experiencing uncontrolled pain.

Authors:  Stephen Clarke; Belinda E Butcher; Andrew J McLachlan; Jeremy D Henson; David Rutolo; Sean Hall; Luis Vitetta
Journal:  PLoS One       Date:  2022-10-14       Impact factor: 3.752

  4 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.